Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
PEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$148.00 - $310.00
Previous CloseN/A
Volume93.15K
Average Volume (3M)436.51K
Market Cap
$10.53B
Enterprise Value$9.15B
Total Cash (Recent Filing)$8.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)807.5
Beta0.74
Next Earnings
Apr 23, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding38,683,650
10 Day Avg. Volume473,934
30 Day Avg. Volume436,513
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.04
Price to Cash Flow (P/CF)52.80
P/FCF Ratio52.40
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.12
Enterprise Value/Ebitda212.57
Forecast
1Y Price Target
$309.50Price Target Upside11.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Penumbra News
PremiumCompany Announcements
Penumbra Announces Board Transition with Kassing’s Retirement---
Bulls Say, Bears Say
Bulls Say
Financial PerformancePEN delivered a strong Q4, with revenue of $315.5M, beating both the estimate and consensus.
Market PerformancePEN's arterial thrombectomy business is recognized as the second largest and second fastest growing segment in the US thrombectomy market.
Product DevelopmentThe launch of new products like Lightning Bolt 6X with TraX is expected to boost PEN's arterial thrombectomy segment.
Bears Say
Investor ChallengesInvestors have faced challenges in evaluating PEN's performance due to changes in its reporting structure.
Medical SkepticismA doctor wasn't totally convinced that modulated aspiration would drive a significant enough change to patient outcomes.
---
Ownership Overview
3.52% Insiders
40.73% Mutual Funds
― Other Institutional Investors
33.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $310.00 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $10.53B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Apr 23, 2025 which is in 5 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Feb 18, 2025. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.896 by $0.074.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 0.67.
How many shares outstanding does Penumbra have?
Penumbra has 38,683,650 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.97 in its last earnings report, beating expectations of $0.896. Following the earnings report the stock price went up 12.031%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in PEN
---
Penumbra Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$309.50 (11.42% Upside)
$309.50 (11.42% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 82.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.7%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.24%
12-Months-Change
Fundamentals
Return on Equity
1.20%
Trailing 12-Months
Asset Growth
-1.49%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. (PEN) is a global healthcare company specializing in innovative medical devices and technologies. The company primarily focuses on developing, manufacturing, and marketing products for treating a wide range of medical conditions, particularly in the fields of vascular and neurovascular health. Penumbra's core products include devices for thrombectomy, embolization, and access technologies used in procedures to address stroke, aneurysms, and other vascular conditions. The company is dedicated to advancing healthcare through research and development, producing solutions that cater to the needs of healthcare professionals and patients worldwide.
---
PEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Penumbra demonstrated robust growth and profitability in its U.S. thrombectomy business, driven by product innovation and strategic expansion. However, international revenue challenges, particularly in China, and costs associated with the exit from Immersive Healthcare slightly tempered overall performance. The overall sentiment is positive due to strong domestic growth and future strategic initiatives outweighing the international setbacks.Read More>---
PEN Stock 12 Month Forecast
Average Price Target
$309.50
▲(11.42% Upside)
Technical Analysis
Best Analysts Covering PEN
1 Year
1 Year Success Rate
14/19 ratings generated profit
1 Year Average Return
+20.70%
reiterated a buy rating 3 days ago
Copying Shagun Singh Chadha's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +20.70% per trade.
---